Raptor Pharma (RPTP) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Raptor Pharmaceutical Corp. Reports First Quarter 2016 Financial Results
May 5, 2016 4:09 PM EDTPROCYSBI® Global Net Revenue Increased 34% Year-Over-Year, to $27.5 Million
2016 Non-GAAP Operating Expense Guidance Lowered to $125 $135 Million Â
Full-Year 2016 Revenue Guidance Maintained at $115 $125 Million
NOVATO, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (NASDAQ: RPTP) (Raptor or the Company), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases, today announced its financial results for the first quarter of 2016 and provided an update on recent corporate developments.
... More